Blueprint Medicines (BPMC) Stock Price, News & Analysis

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 3 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares.
View BPMC analyst ratings or view top-rated stocks.

14 brokerages have issued 12 month price targets for Blueprint Medicines' shares. Their BPMC share price targets range from $43.00 to $115.00. On average, they predict the company's share price to reach $85.43 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price.
View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts.

Blueprint Medicines' stock was trading at $92.24 at the beginning of 2024. Since then, BPMC stock has decreased by 7.7% and is now trading at $85.18.
View the best growth stocks for 2024 here.

Blueprint Medicines saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 4,370,000 shares, a decrease of 15.1% from the March 15th total of 5,150,000 shares. Based on an average trading volume of 786,700 shares, the days-to-cover ratio is presently 5.6 days.
View Blueprint Medicines' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BPMC earnings forecast.

Blueprint Medicines Co. (NASDAQ:BPMC) announced its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts' consensus estimates of ($2.04) by $0.22. The biotechnology company earned $71.96 million during the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative trailing twelve-month return on equity of 191.56%. The business's revenue was up 85.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.65) earnings per share.

ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Biotechnology & Genome ETF (PBE), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Harbor Corporate Culture Small Cap ETF (HAPS) and BlackRock Future Health ETF (BMED).

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' stock is owned by many different institutional and retail investors. Top institutional shareholders include Clarus Wealth Advisors (0.00%). Insiders that own company stock include Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain.
View institutional ownership trends.

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.